Reverse vaccinology of enterotoxigenic E. coli
Reverse vaccinology of enterotoxigenic E. coli
批准号:
8518225
负责人:
Philip Ross Hardwidge
金额:
$21.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2015-07-31
关键词:
AdherenceAmericanAnimal ModelAntigensBasic ScienceBiological AssayBioterrorismCategoriesCell Culture TechniquesCell surfaceChildDeveloping CountriesDiarrheaDiseaseDisease OutbreaksDrug FormulationsEnterobacteriaceaeEscherichia coliEscherichia coli AdhesinsEscherichia coli InfectionsEscherichia coli ProteinsEscherichia coli VaccinesHealthHumanImmune SeraImmune systemImmunityImmunizationIn VitroInfant MortalityIntestinesMalnutritionMediatingMembraneMembrane ProteinsMicrobiologyMilitary PersonnelModelingMusNational Institute of Allergy and Infectious DiseasePerformanceProteinsProteomeProteomicsRecombinantsRegimenResearchRiskScourgeSourceSurfaceSurface AntigensSystemTechniquesTestingVaccinationVaccine AntigenVaccinesVirulenceWorkburden of illnessenteric pathogenenterotoxigenic Escherichia coliexperiencefoodbornegenome sequencinginnovationneglectnovelnovel strategiesnovel therapeuticsnovel vaccinesoperationpathogenprotective efficacyprotein profilingresearch studyvaccine candidatevaccine developmentvaccinologyvolunteer
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Significance of the proposed research. Diarrheal disease caused by enteric bacteria is an important endemic health threat and a major source of food-borne disease. Diarrheal pathogens also remain an important health concern in current military operations and in bioterrorism. In spite of the appreciated magnitude of the threat to both general human health and the severe inhibition of military performance caused by ETEC, we still do not have an effective vaccine, nor do we fully understand the virulence determinants responsible for intestinal colonization and subsequent diarrheal disease. Basic research is needed to identify new therapeutic and vaccine targets. The objective of this application is to use quantitative proteomic protein profiling to discover broadly conserved antigens that will permit development of a vaccine efficacious against ETEC. The primary need that motivates this research objective is that despite the significant effort and expense that has been employed in vaccine trials using ETEC adhesins, none of these vaccines have been especially effective in mediating cross- protective immunity, and some trials have even had significant health risks. Alternative vaccine targets and strategies are demanded. We will utilize our proven experience in ETEC microbiology and quantitative proteomics to characterize novel ETEC vaccine antigens. We will do this by identifying novel surface-exposed ETEC proteins likely to be recognized by the host immune system. We show in preliminary studies that the proposed approach rapidly and economically identifies conserved, surface-exposed ETEC proteins, independent of strain-specific CFs, which can be purified and used in protection assays in a robust animal model of ETEC virulence. The specific aims are to: 1) Characterize ETEC outer membrane proteomes using quantitative proteomic profiling, 2) Produce recombinant ETEC proteins and antisera, and 3) Immunize mice with recombinant ETEC antigens and quantify their ability to protect against an otherwise lethal challenge with ETEC. The proposed research is significant and innovative because it introduces a novel strategy for protective antigen discovery for a neglected pathogen responsible for causing an enormous global diarrheal disease burden. Indeed, we have already discovered seventeen surface-exposed antigens that are potential components of a new ETEC vaccine formulation. Additionally, these experiments will optimize proteomic strategies needed to characterize vaccine candidates in other enteric pathogens.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3389/fcimb.2018.00132
发表时间:
2018
期刊:
Frontiers in cellular and infection microbiology
影响因子:
5.7
作者:
[Hays MP, Houben D, Yang Y, Luirink J, Hardwidge PR]
通讯作者:
Hardwidge PR
DOI:
10.1371/journal.pntd.0003924
发表时间:
2015
期刊:
PLoS neglected tropical diseases
影响因子:
3.8
作者:
[Kumar A, Hays M, Lim F, Foster LJ, Zhou M, Zhu G, Miesner T, Hardwidge PR]
通讯作者:
Hardwidge PR
Vaccinating with conserved Escherichia coli antigens does not alter the mouse intestinal microbiome.
DOI:
10.1186/s13104-016-2208-y
发表时间:
2016-08-11
期刊:
BMC research notes
影响因子:
1.8
作者:
[Hays MP, Ericsson AC, Yang Y, Hardwidge PR]
通讯作者:
Hardwidge PR
T3SS Effector Regulation of Bacterial Metabolism
-
批准号:10425770
-
项目类别:
-
资助金额:$18.65万
-
财政年份:2022
-
负责人:Philip Ross Hardwidge
-
依托单位:
Molecular and Cellular Biology Core
-
批准号:10642676
-
项目类别:
-
资助金额:$34.11万
-
财政年份:2020
-
负责人:Philip Ross Hardwidge
-
依托单位:
Molecular and Cellular Biology Core
-
批准号:10397674
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2020
-
负责人:Philip Ross Hardwidge
-
依托单位:
Functions of Translocated Bacterial Glycosyltransferases
-
批准号:9222103
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2016
-
负责人:Philip Ross Hardwidge
-
依托单位:
An enterotoxigenic E. coli protein that antagonizes the NF-kappaB pathway
-
批准号:8891351
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effectors targeting the IKK/NF-kB pathway
-
批准号:8791592
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2013
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effectors targeting the IKK/NF-kB pathway
-
批准号:9188797
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2013
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effectors targeting the IKK/NF-kB pathway
-
批准号:8495491
-
项目类别:
-
资助金额:$8.81万
-
财政年份:2013
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effectors targeting the IKK/NF-kB pathway
-
批准号:8589734
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2012
-
负责人:Philip Ross Hardwidge
-
依托单位:
Reverse vaccinology of enterotoxigenic E. coli
-
批准号:8589931
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2012
-
负责人:Philip Ross Hardwidge
-
依托单位:
Delivery of a bacterial inhibitor of NF-kB to colon tumors
-
批准号:8296462
-
项目类别:
-
资助金额:$0.83万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effector inhibition of type I interferon
-
批准号:8227954
-
项目类别:
-
资助金额:$2.9万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Delivery of a bacterial inhibitor of NF-kB to colon tumors
-
批准号:8184998
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effector inhibition of type I interferon
-
批准号:8609163
-
项目类别:
-
资助金额:$15.85万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Delivery of a bacterial inhibitor of NF-kB to colon tumors
-
批准号:8636895
-
项目类别:
-
资助金额:$6.67万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effector inhibition of type I interferon
-
批准号:8088850
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2011
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effector subversion of host protein trafficking
-
批准号:7862895
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2010
-
负责人:Philip Ross Hardwidge
-
依托单位:
Disruption of NF-kB signaling by diarrheagenic Escherichia coli
-
批准号:8129920
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2010
-
负责人:Philip Ross Hardwidge
-
依托单位:
Bacterial effector subversion of host protein trafficking
-
批准号:8019137
-
项目类别:
-
资助金额:$7.43万
-
财政年份:2010
-
负责人:Philip Ross Hardwidge
-
依托单位:
MODULATION OF NF-KB SIGNALLING BY E COLI PROTEIN KINASES
-
批准号:8168402
-
项目类别:
-
资助金额:$26.93万
-
财政年份:2010
-
负责人:Philip Ross Hardwidge
-
依托单位:
海外基金